Latest Ratios: P/E Ratio N/A · EV/EBITDA N/A · ROE -42.7%. (2023–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Market Cap | — | — | — |
| Enterprise Value | — | — | — |
| P/E Ratio → | — | — | — |
| P/S Ratio | — | — | — |
| P/B Ratio | — | — | — |
| P/FCF | — | — | — |
| P/OCF | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| EV / Revenue | — | — | — |
| EV / EBITDA | — | — | — |
| EV / EBIT | — | — | — |
| EV / FCF | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Gross Margin | 30.4% | 30.4% | 43.8% |
| Operating Margin | -286.5% | -286.5% | -2.8% |
| Net Profit Margin | -276.6% | -276.6% | 3.9% |
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| ROE | -42.7% | -42.7% | 59.0% |
| ROA | -39.3% | -39.3% | 4.2% |
| ROIC | -63.3% | -63.3% | — |
| ROCE | -44.1% | -44.1% | -42.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 2.07 |
| Debt / EBITDA | — | — | — |
| Net Debt / Equity | — | -0.47 | -1.72 |
| Net Debt / EBITDA | — | — | — |
| Debt / FCF | — | — | — |
| Interest Coverage | -1893.69 | -1893.69 | -4.59 |
Net cash position: cash ($3M) exceeds total debt ($22555)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Current Ratio | 13.18 | 13.18 | 0.91 |
| Quick Ratio | 13.04 | 13.04 | 0.68 |
| Cash Ratio | 11.91 | 11.91 | 0.29 |
| Asset Turnover | — | 0.07 | 1.09 |
| Inventory Turnover | 9.51 | 9.51 | 2.83 |
| Days Sales Outstanding | — | 187.95 | 102.61 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Dividend Yield | — | — | — |
| Payout Ratio | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 |
|---|---|---|---|
| Earnings Yield | — | — | — |
| FCF Yield | — | — | — |
| Buyback Yield | — | — | — |
| Total Shareholder Yield | — | — | — |
| Shares Outstanding | — | $0 | $0 |
Rapid Cash Runway Depletion
As reported in initial financial filings, YD Bio's operating margin of -286.45% underscores a high-burn business model where research and development expenditures significantly outpace the company's current revenue generation, which remains limited to a modest $510,360 in trailing twelve-month diagnostic and service-based sales.
The current gross margin of 30.44% appears structurally low for a biotechnology firm, suggesting that the cost of goods sold—likely driven by manual laboratory labor and specialized reagents—remains disproportionately high relative to current pricing. Investors should monitor whether the company can transition from manual laboratory-developed tests to automated, high-throughput diagnostic kits to achieve the scale necessary for margin expansion.
According to recent financial disclosures, YD Bio maintains a cash position of $3.1M, which, when evaluated against its high-burn R&D-focused operating model, suggests a precarious liquidity buffer that may necessitate external capital infusion within the next 12 to 18 months to sustain ongoing clinical development activities.
The lack of recurring revenue streams makes the company highly sensitive to capital market volatility, as it currently relies on external financing to fund its operations. Given the absence of debt, the firm retains some strategic optionality, but the rapid depletion of cash reserves warrants close scrutiny of the company's ability to reach critical clinical milestones before requiring further dilution.
Based on reported figures, YD Bio maintains a 0% debt-to-equity ratio, indicating that the company has avoided leverage during its initial setup phase, which may provide a degree of strategic optionality as it navigates the high-risk, capital-intensive environment of early-stage biotechnology research and development.
While the absence of debt is a positive indicator of fiscal discipline during the startup phase, it also reflects the company's reliance on equity-based financing, which is inherently more expensive and dilutive for shareholders. Investors should monitor whether management maintains this conservative capital structure as the company moves toward more capital-intensive clinical trial phases.
As suggested by the company's February 2024 incorporation, the market's reliance on traditional revenue-based valuation multiples for YD Bio is likely misapplied, as the current $510,360 in revenue may include non-recurring government grants that do not reflect sustainable commercial product-market fit for its diagnostic kits.
Investors should prioritize clinical trial milestones and patent grant density over standard P/S or P/E ratios, which are currently meaningless given the company's pre-profit status. The 'W' suffix in the ticker further complicates valuation, as the potential for significant share count dilution from outstanding warrants may obscure the true equity value for long-term holders.
Includes 30+ ratios · 2 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying YDESW stock.
YD Bio Limited Warrants's return on equity (ROE) is -42.7%. The historical average is 8.1%.
Based on historical data, YD Bio Limited Warrants is trading at valuation metrics that vary. Compare with industry peers and growth rates for a complete picture.
YD Bio Limited Warrants has 30.4% gross margin and -286.5% operating margin.